Patients with osteochondral defects of the talus and previously failed microfractures who underwent malleolar osteotomy and implantation of Belgrade, MT-based Bacterin’s allograft bone graft material had positive outcomes at two-year follow-up, according to a study epublished in July by The Journal of Foot & Ankle Surgery.
Two years after surgery, the 12 patients included in the study had significantly reduced pain and disability compared with preoperative values.
Bacterin’s OsteoSponge SC is approved as a bone void filler to treat defects in the subchondral region of articulating joints.
